United Therapeutics Community
Our community narratives are driven by numbers and valuation.
Value any stock for free in seconds
Get alerts and valuation updates
Participate in discussions
WA
Consensus Narrative from 14 Analysts
Future Success With Tyvaso And Ralinepag Will Improve Pulmonary Health Care
Key Takeaways Strategic advancements in pulmonary health products and organ technologies could significantly boost revenue and open high-growth markets. Accelerated share repurchase programs may improve earnings per share, reflecting a focus on shareholder value.
View narrativeUS$393.74
FV
8.5% undervalued intrinsic discount9.42%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
1 day ago author updated this narrative